Presenting Pivotal Phase 3 Sickle Cell Data at EHA 2026- Agios Pharmaceuticals
Agios Pharmaceuticals shared a post on LinkedIn:
“Agios News: Today, during the Plenary Abstracts Session at EHA 2026, we presented detailed results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.
This oral presentation included new transfusion burden and hemoglobin responder analyses that reinforce the strong anti-hemolytic profile of our first-in-class PK activator.
Read the results.”
Mohamed A., Franchise Director, Blood Disorders, Rare Disease GCC at NewBridge Pharmaceuticals, shared this post on LinkedIn:
“Results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community
-
Sep 19, 2026, 10:46Anton Farkas: Mechanical Thrombectomy for Acute PE in Early Pregnancy
-
Sep 19, 2026, 10:40Marjolein Smidt: ASH Raises Ferritin Thresholds for Iron Deficiency